Showing results (41-50 of 123) with videos related to
Sort By:
Pageof 13
Anticancer Research|December 11, 2013
Phase II trial of pemetrexed continuation--maintenance after carboplatin-based induction in untreated non-squamous non-small cell lung cancerSeigo Minami, Takashi Kijima, Kiyoshi Komuta, et al.Medicine|May 5, 2022
Manual route modification using an oblique method following automatic virtual bronchoscopic navigationTakako Inoue, Takahisa Kawamura, Kei Kunimasa, et al.Respiratory Medicine Case Reports|April 30, 2020
Infectious pericarditis caused by Gemella sanguinis induced by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA): A case reportTakako Inoue, Tatsuya Nishikawa, Kei Kunimasa, et al.American Journal of Physiology. Lung Cellular and Molecular Physiology|October 12, 2004
Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxideHiroshi Kida, Mitsuhiro Yoshida, Shigenori Hoshino, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activationHiroko Endo, Jiro Okami, Hiroaki Okuyama, et al.Future Oncology (London, England)|July 15, 2020
Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutationFumio Imamura, Madoka Kimura, Yukihiro Yano, et al.Investigational New Drugs|June 20, 2020
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumabMotohiro Tamiya, Kei Kunimasa, Kazumi Nishino, et al.JTO Clinical and Research Reports|April 3, 2023
First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWNHidetoshi Hayashi, Shunsuke Teraoka, Yasushi Goto, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 17, 2006
[Clinical efficacy of TS-1 in refractory bone recurrence of a postoperative squamous lung cancer patient]Tadashi Osaki, Takayuki Takimoto, Mitsugi Furukawa, et al.Lung Cancer Management|April 30, 2020
Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLCFumio Imamura, Takako Inoue, Kei Kunimasa, et al.Pageof 13